What is Mineralys Therapeutics, Inc.'s D&A?

Mineralys Therapeutics, Inc. (MLYS) reported D&A of $6K in Q1 2026.

How has Mineralys Therapeutics, Inc.'s D&A changed year-over-year?

Mineralys Therapeutics, Inc.'s D&A decreased by 60.0% year-over-year, from $15K to $6K.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Mineralys Therapeutics, Inc. MLYS D&A

D&A at other companies

Aurinia PharmaceuticalsAUPH

$4.82M-0.8%

Crinetics PharmaceuticalsCRNX

$1.16M+25.4%

CytokineticsCYTK

$3.38M+46.9%

Tenet HealthcareTHC

$229M+11.2%

MedtronicMDT

$716M-14.8%

Boston ScientificBSX

$351M+8.0%

Other financials

Income statement

See full

Operating income-$45.3M-2.0%

Net income-$39.3M+6.8%

EPS (diluted)-$0.47+40.5%

Balance sheet

See full

Cash & equivalents$1.2M-14.6%

Total equity$638.1M+86.8%

Total assets$652.9M+83.9%

Cash flow

See full

Operating cash flow-$39.5M+13.2%

CapEx$15.0K—

Free cash flow-$37.9M+43.3%

Valuation

See full

Market cap$2.26B+124%

Returns & leverage

See full

Return on equity-31%-9.6pp

Current ratio44.3×+17.8×

Where this comes from

Reported directly by Mineralys Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: Mineralys Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Mineralys Therapeutics, Inc.'s d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Mineralys Therapeutics, Inc.'s D&A?: Mineralys Therapeutics, Inc. (MLYS) reported D&A of $6K in Q1 2026.
How has Mineralys Therapeutics, Inc.'s D&A changed year-over-year?: Mineralys Therapeutics, Inc.'s D&A decreased by 60.0% year-over-year, from $15K to $6K.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.